Industry News
EyRIS and Optometrist Warehouse Join Forces for AI-Driven Diabetic Retinopathy Study
EyRIS, a Singapore-based healthcare technology company specializing in AI-driven solutions for eye diseases, has joined forces with Optometrist Warehouse, a division of the Chemist Warehouse Group in Australia, in a groundbreaking initiative. They have signed a Memorandum of Understanding (MOU) to collaborate on a pioneering study that focuses on the effectiveness of AI in screening for diabetic retinopathy. This collaboration is a significant milestone in the healthcare field, demonstrating the potential benefits of AI-driven solutions in enhancing patient outcomes and cost-effectiveness.
Diabetic retinopathy, a prevalent complication of diabetes, is one of the leading causes of blindness among adults worldwide. According to the Australian Diabetes Society, there are currently over 1.5 million Australians living with diabetes, and this number is expected to rise significantly in the coming decade. Early detection and intervention are crucial in preventing vision loss and related complications.
The study will leverage EyRIS's advanced AI algorithms and Optometrist Warehouse's expertise, which is backed by the extensive network of pharmacies across Australia through Chemist Warehouse. Together, they aim to evaluate the effectiveness of AI-driven screening for diabetic retinopathy. By utilizing EyRIS's cutting-edge technology, which analyzes retinal images to identify signs of diabetic retinopathy, the study aims to demonstrate the efficiency and efficacy of AI in identifying at-risk patients and facilitating early intervention.
Mr. Lai Teik Kin, CEO of EyRIS, expressed his enthusiasm for the collaboration, stating, "We are delighted to partner with Optometrist Warehouse on this groundbreaking study. By harnessing the power of AI, we can revolutionize the screening process for diabetic retinopathy, ensuring early detection and timely treatment for patients. Our technology has the potential to transform healthcare delivery, saving lives, and reducing healthcare costs."
Optometrist Warehouse, with its innovative mission to enhance health outcomes by forging connections between pharmacy and optometry, acknowledges the transformative impact of AI in the medical field. Mr. Peter Larsen, MD of Optometrist Warehouse and a renowned leader in improving eye health services, commented, "We are proud to collaborate with EyRIS in exploring the possibilities of AI for diabetic retinopathy screening. This study aligns with our mission to enhance healthcare outcomes for all Australians. By leveraging EyRIS's AI expertise, we can improve the accessibility and affordability of early screening, empowering both patients and healthcare providers."
The collaboration between EyRIS and Optometrist Warehouse underscores the commitment of both organizations to harness technological advancements for the betterment of healthcare. The potential benefits of AI-driven diabetic retinopathy screening include reducing the burden on healthcare systems, minimizing unnecessary referrals, and enabling targeted interventions, ultimately leading to improved patient outcomes.
The study will be conducted over a span of 36 months and involve a large sample size of diabetic patients from various regions across Australia.
